Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB12 vs Keytruda in advanced/metastatic non-squamous NSCLC
2024-515853-48-00Phase 3Authorised
- Sponsor
- mAbxience
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing MB12 with Keytruda (2 arms). Planned start Sep 2025; status: authorised.
02
Drugs
Pembroxpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515853-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515853-48-00.